Hepatic arterial infusion chemotherapy in patients with unresectble hepatocellular carcinoma: 3-year survival update
Aims Hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin plus raltitrexed showed a promising response rate in patients with unresectable hepatocellular carcinoma (HCC) in a phase 2 trial. Here, we report the updated 3-year survival data after enrollment.Methods In this prospective trial,...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis
2025-12-01
|
| Series: | Hepatic Oncology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/20450923.2025.2516994 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Aims Hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin plus raltitrexed showed a promising response rate in patients with unresectable hepatocellular carcinoma (HCC) in a phase 2 trial. Here, we report the updated 3-year survival data after enrollment.Methods In this prospective trial, we enrolled patients with intermediate and advanced unresectable HCC. The treatment was HAIC with raltitrexed plus oxaliplatin.Results The objective responses were achieved in 19 (48.7%) of 39 patients in the intention-to-treat population. The median overall survival and progress-free survival were 11.2 and 6.5 months, respectively.Conclusion The 3-year survival update confirmed the antitumor activity and long-term survival benefit of HAIC with oxaliplatin plus raltitrexed in patients with unresectable HCC.Clinical trial registration www.chictr.org.cn identifier is ChiCTR-OOC-17014182. |
|---|---|
| ISSN: | 2045-0923 2045-0931 |